Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (ADVATE rAHF-PFM): A Phase 4 Study to Determine the Pharmacokinetic Response of Patients Diagnosed With Severe Hemophilia A to Different Doses of ADVATE rAHF-PFM

NCT00289536 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT00289536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00289536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (ADVATE rAHF-PFM): A Phase 4 Study to Determine the Pharmacokinetic Response of Patients Diagnosed With Severe Hemophilia A to Different Doses of ADVATE rAHF-PFM
Lead sponsor
Baxalta now part of Shire
Phase
Phase 4
Overall status
Completed
Start date
February 2, 2006
Completion date
April 1, 2007
Enrollment
38 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a